N-of-1 and rapid platform trials
Building a trial around one patient, or letting one trial swap drugs in and out as evidence accumulates.
Bespoke antisense drugs have been made for single patients with rare neurological disease under an FDA pathway, and the same logic is being applied to private neoantigen and splice-targeting therapies in cancer. Adaptive platform trials such as I-SPY 2 in breast cancer graduate or drop arms on interim Bayesian analysis, which is the scalable version of the same idea. The obstacles are manufacturing, cost, and how to learn anything generalisable from a single case.
How it works
Either an intervention is designed for one person's mutation, or a master protocol keeps a shared control arm while arms enter and leave, so each new question costs less.
- Reaches patients whose subgroup will never be studied
- Platform designs reuse the control arm
- Faster answers from fewer patients
- Extreme cost per patient for true N-of-1
- Interpretation without randomisation is fragile
- Regulatory and reimbursement paths unclear
Latest papers
topQuery for this technology: (TITLE:"N-of-1 and rapid platform trials" OR ABSTRACT:"N-of-1 and rapid platform trials") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about N-of-1 and rapid platform trials, not a curated reading list.